Cardiovascular Risk

Strategic objectives

  • To maintain the clinical trials platform.
  • To develop a line of research with clinical application (“translational research”).
  • To identify new biomarkers for the prevention, prognosis, and therapeutic efficacy of cardiovascular disease.
  • To study the efficacy of new drugs in cardiovascular disease.
  • To maintain a line of research that demonstrates leadership and is of interest for the IdISSC Strategic Plan, increasing the group’s funding and the quality of publications.

Lines of research

  • Complications in Internal Medicine patients.
  • Studies for the prevention of pre-eclampsia.
  • Non-invasive haemodynamics.
  • Epidemiology of metabolic syndrome and diabetes mellitus.
  • Molecular mechanisms and prognostic markers in heart failure syndrome in order to identify new therapeutic approaches.
  • Molecular mechanisms and prognostic markers in atherosclerosis in order to identify new therapeutic approaches.
  • To study the association between gut microbiota profile and/or bacterial metabolite production in the development and progression of cardiovascular disease.
  • To study of the relationship between the exposome and the development and progression of cardiovascular disease.

Other members of the group

  • María Abad Cardiel
  • Sandra Ballesteros Rodrigálvarez
  • Aránzazu Barbero Pedraz
  • Rafael Borge García
  • Arturo Corbatón Anchuelo
  • Natalia De Las Heras Jiménez
  • Ana María García Ruiz
  • Jose Antonio Garcia Donaire
  • Manuel Mendez Bailon
  • Javier (Ciber) Modrego Martin
  • Angel Manuel Molino Gonzalez
  • Ángel Nieto Sánchez
  • Adriana Ortega Hernández
  • Jose María Pedrajas Navas
  • Matilde Rodríguez Cerrillo

Publications

Projects